On-demand | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

A focus on obesity management in the UK

Obesity is a serious chronic condition associated with great physical and psychological impact on the quality of life of those who live with it – as well as placing pressure on the finances and resources of the NHS. Yet healthcare professionals have limited options for helping patients to manage the condition: until very recently, there have been limited pharmacological treatment options available apart from Orlistat.

These videos provide an update on the pharmacotherapy for obesity available to healthcare professionals in the NHS: Saxenda® (liraglutide 3mg), the NICE Single Technology Appraisal (STA) for Saxenda®, which of your patients may be suitable for this therapy, and how the guidance could affect the way you treat your patients with obesity.

This promotional resource is organised and funded by Novo Nordisk.
The information presented is intended for UK-based healthcare professionals.

Changing Paradigms: A focus on
obesity management in the UK

The landscape of obesity management - What do we know?

Prof John Wass

Play Video

Saxenda® (liraglutide 3mg) and the current evidence

Dr Carel Le Roux

Play Video

Saxenda® NICE Single Technology Appraisal (STA)
and what you need to know

Dr Abd Tahrani (Chair)

Play Video

Prof Carel Le Roux

Consultant in Metabolic Medicine, King's College Hospital, London

Professor Carel Le Roux graduated from medical school in Pretoria South Africa, completed his specialist training in metabolic medicine at St Bartholomew’s Hospitals and the Hammersmith Hospitals. He obtained his PhD from Imperial College London where he later took up a faculty position. He moved to University College Dublin for the Chair in Experimental Pathology and he is now a Director of the Metabolic Medicine Group. He currently coordinates an Innovative Medicine Initiative project on obesity. He previously received a President of Ireland Young Researcher Award, Irish Research Council Laurate Award, Clinician Scientist Award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research Fellowship for his work on how the gut talks to the brain.

Dr Abd Tahrani (Chair)

Senior Lecturer in Endocrinology and Obesity Medicine, University of Birmingham; Consultant Endocrinologist and Bariatric Physician, University Hospitals Birmingham NHS Foundation Trust

Abd Tahrani is a Senior Lecturer in Metabolic Endocrinology and Obesity Medicine at the University of Birmingham (UoB). Abd is also an Honorary Consultant in Endocrinology, Diabetes & Weight Management, and the lead for weight management research and diabetic neuropathy services at the University Hospitals Birmingham NHS Foundation Trust. He is the lead for translational research in the Centre of Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners.

Abd received several awards including NIHR research training fellowship (2008), NIHR Clinician Scientist (2012), the American Academy of Sleep Medicine Young investigator award in OSA research (2013), SCOPE National & International Fellowships from the World Obesity Federation in (2014 & 2020). Abd’s research themes are: 1) the metabolic consequences of sleep-related disorders, 2) obesity management & health care delivery, 3) diabetes-related neuropathy. 

Abd has published over 150 peer reviewed articles and delivered more than 100 invited talks in the leading conferences globally.  Abd is a trustee of ASO (UK), a panel member of the NIHR RfPB, and the British Sleep Society Research Committee. Abd is also and an Expert advisor to NICE and a member of the strategic council of the Obesity All Party Parliamentary Group (Obesity APPG). He is the co-Chair of the Clinical practice and Obesity Management Committee of ASO (UK) and a member of the Obesity Policy Engagement Network (OPEN) UK. He is a regular peer reviewer to the leading journals and research funding organisations. Abd is an associate editor for the European Journal of Endocrinology and the Diabetes Section Editor for BMC Endocrine Disorders.

Prof John Wass

Professor of Endocrinology, University of Oxford

John Wass is the Professor of Endocrinology at Oxford University and was Head of the Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Oxford, UK until 2012.

His research interests include all pituitary tumours, especially acromegaly, adrenal disease, angiogenesis in endocrinology, and the genetics of osteoporosis and thyroid disease.

Since 1975 he has published over 385 articles in scientific journals and as well as written many reviews and chapters in textbooks including the Oxford Textbook of Medicine and DeGroot’s Textbook of Endocrinology.  He has also edited a number of different textbooks including the Oxford Textbook of Endocrinology, Clinical Endocrine Oncology and the Oxford Handbook of Endocrinology (3 editions).  He was President of the European Federation of Endocrine Societies from 2001-2003 and was Chairman of the Society for Endocrinology (2006-2009.  He has also served as President of the Pituitary Society.

He has won a number of prizes and given named lectures including the Jubilee Prize of the Society for Endocrinology.  He was recently in June last year awarded the Distinguished Physician of the Year Award by the American Endocrine Society; the first non American to ever receive this award.

Amongst his charitable activities, he is Patron of the St. Pauls Way School (with Professor Brian Cox) and he founded the Pituitary Foundation.

He was Academic Vice President of the Royal College of Physicians in London, from August 2012 until August 2015.

He chaired the Royal College of Physicians Working Party ‘Action on Obesity: Comprehensive Care for All’ published in January 2013, and has been involved improving services for patients with obesity.

Recently he presented the acclaimed documentary ‘The Fantastical World of Hormones’ on BBC4.

Prescribing information for Saxenda® (liraglutide) can be accessed by clicking here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.
This promotional resource is organised and funded by Novo Nordisk.
The information presented is intended for UK-based healthcare professionals.

Job code: UK21SX00082 | Date of preparation: March 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.